PDCD1 and cervical carcinoma: Given that clinical benefits of pembrolizumab in cervical cancer are still sparse and limited, there is an unmet need for more trials and studies that explore the role of pembrolizumab in addition to other immune checkpoint inhibitors (e.g., PD-1 (nivolumab and cemiplimab) and PD-L1 inhibitors (e.g., durvalumab, avelumab, and atezolizumab) (64).